Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis

Abstract In order for measurement-based care to be implemented, there is a need for brief rating instruments that can be administered in a short amount of time, but that are still sufficiently informative. Here, we assessed the drug–placebo sensitivity of the six-item subscale (PANSS-6) of the 30-it...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fredrik Hieronymus, Pernille Kølbæk, Christoph U. Correll, Søren D. Østergaard
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Psychiatry RC435-571
Acceso en línea:	https://doaj.org/article/6e2551eb683541798116ff0d4547bbfa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6e2551eb683541798116ff0d4547bbfa
record_format	dspace
spelling	oai:doaj.org-article:6e2551eb683541798116ff0d4547bbfa2021-12-02T15:09:06ZAntipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis10.1038/s41537-021-00168-x2334-265Xhttps://doaj.org/article/6e2551eb683541798116ff0d4547bbfa2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41537-021-00168-xhttps://doaj.org/toc/2334-265XAbstract In order for measurement-based care to be implemented, there is a need for brief rating instruments that can be administered in a short amount of time, but that are still sufficiently informative. Here, we assessed the drug–placebo sensitivity of the six-item subscale (PANSS-6) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) using a large collection of patient-level data (n = 6685) from randomized controlled trials of risperidone and paliperidone. When analyzing the data by study, we found no material difference in mean effect sizes (ES) between the two measures (PANSS-30 ES = 0.45, PANSS-6 ES = 0.44; p = 0.642). Stratifying the pooled population according to several putative effect moderators (e.g., age, formulation, dose, or diagnosis) generally yielded no meaningful ES differences between the two measures. Similarly, early improvement (≥20% improvement at week 1) on the PANSS-6 predicted subsequent response (≥40% improvement at endpoint) as well as the analog prediction using PANSS-30. Finally, cross-sectional symptom remission assessed via the PANSS-6 showed very good agreement (sensitivity = 100%, specificity = 98%) with cross-sectional symptom remission defined by the Remission in Schizophrenia Working Group.Fredrik HieronymusPernille KølbækChristoph U. CorrellSøren D. ØstergaardNature PortfolioarticlePsychiatryRC435-571ENnpj Schizophrenia, Vol 7, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Psychiatry RC435-571
spellingShingle	Psychiatry RC435-571 Fredrik Hieronymus Pernille Kølbæk Christoph U. Correll Søren D. Østergaard Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
description	Abstract In order for measurement-based care to be implemented, there is a need for brief rating instruments that can be administered in a short amount of time, but that are still sufficiently informative. Here, we assessed the drug–placebo sensitivity of the six-item subscale (PANSS-6) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) using a large collection of patient-level data (n = 6685) from randomized controlled trials of risperidone and paliperidone. When analyzing the data by study, we found no material difference in mean effect sizes (ES) between the two measures (PANSS-30 ES = 0.45, PANSS-6 ES = 0.44; p = 0.642). Stratifying the pooled population according to several putative effect moderators (e.g., age, formulation, dose, or diagnosis) generally yielded no meaningful ES differences between the two measures. Similarly, early improvement (≥20% improvement at week 1) on the PANSS-6 predicted subsequent response (≥40% improvement at endpoint) as well as the analog prediction using PANSS-30. Finally, cross-sectional symptom remission assessed via the PANSS-6 showed very good agreement (sensitivity = 100%, specificity = 98%) with cross-sectional symptom remission defined by the Remission in Schizophrenia Working Group.
format	article
author	Fredrik Hieronymus Pernille Kølbæk Christoph U. Correll Søren D. Østergaard
author_facet	Fredrik Hieronymus Pernille Kølbæk Christoph U. Correll Søren D. Østergaard
author_sort	Fredrik Hieronymus
title	Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
title_short	Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
title_full	Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
title_fullStr	Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
title_full_unstemmed	Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
title_sort	antipsychotic-placebo separation on the panss-6 subscale as compared to the panss-30: a pooled participant-level analysis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6e2551eb683541798116ff0d4547bbfa
work_keys_str_mv	AT fredrikhieronymus antipsychoticplaceboseparationonthepanss6subscaleascomparedtothepanss30apooledparticipantlevelanalysis AT pernillekølbæk antipsychoticplaceboseparationonthepanss6subscaleascomparedtothepanss30apooledparticipantlevelanalysis AT christophucorrell antipsychoticplaceboseparationonthepanss6subscaleascomparedtothepanss30apooledparticipantlevelanalysis AT sørendøstergaard antipsychoticplaceboseparationonthepanss6subscaleascomparedtothepanss30apooledparticipantlevelanalysis
_version_	1718387945719726080

Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis

Ejemplares similares